A high-affinity human/mouse cross-reactive monoclonal antibody, specific for VEGFR-2 linear and conformational epitopes.
Vascular endothelial growth factors receptor 2 (VEGFR-2) has been implicated in playing an important role in the formation of new blood vessels in tumors and other diseases. A high affinity human/mouse cross-reactive anti-VEGFR-2 monoclonal antibody (mAb) named A8H1 was established by hybridoma technology. Several immunological methods were used to characterize the A8H1, including ELISA, affinity and kinetics assay, MALDI-TOF MS, WB, IP, IF, FASC and IHC. The results suggested that A8H1 could bind with linear and conformational epitopes of the VEGFR-2 antigen. The mAb had good specific reactivity with three forms of VEGFR-2 in HUVEC, and two forms in NIH-3T3 mouse fibroblast cells, which are regarded as non-expressive for VEGFR-2. The A8H1 mAb associated with intracellular and plasma membranes in HUVEC and with the nuclei in NIH-3T3 cells. This mAb also effectively identified VEGFR-2 over-expressing cells in a number of archived human cancer tissues.
Huang
Jianfei
J
Key Laboratory of Antibody Technique of Ministry of Health, Department of Pathology, Nanjing Medical University, 210029, Nanjing, China.
Tan
Yang
Y
Tang
Qi
Q
Liu
Xinjian
X
Guan
Xiaohong
X
Feng
Zhenqing
Z
Zhu
Jin
J
Hum Pathol. 2007 Oct;38(10):1532-46
17640715
Oncogene. 1997 May 1;14(17):2079-89
9160888
Thromb Haemost. 2008 Apr;99(4):647-50
18392318
Biochim Biophys Acta. 2000 Jun 1;1466(1-2):71-8
10825432
Nat Rev Cancer. 2002 Oct;2(10):795-803
12360282
Curr Drug Targets. 2009 Feb;10(2):158-75
19199912
J Biol Chem. 1992 Mar 25;267(9):6093-8
1556117
Cancer Lett. 1999 Mar 1;136(2):203-13
10355750
J Clin Oncol. 2002 Nov 1;20(21):4368-80
12409337
Expert Opin Investig Drugs. 2007 Jan;16(1):83-107
17155856
Acta Pharmacol Sin. 2004 Oct;25(10):1292-8
15456530
Cancer Metastasis Rev. 1998 Jun;17(2):155-61
9770111
Front Biosci. 2005 May 01;10:1415-39
15769635
Leukemia. 2003 Mar;17(3):604-11
12646950
Nature. 1975 Aug 7;256(5517):495-7
1172191
Mol Pharm. 2009 Jan-Feb;6(1):285-94
19099493
Curr Pharm Des. 2008;14(27):2883-91
18991706
EXS. 2005;(94):209-31
15617481
J Drug Target. 2007 Nov;15(9):623-31
17968716
Histopathology. 2003 Jul;43(1):33-9
12823710
Curr Med Chem. 2007;14(23):2495-516
17979703
Biotechnol Lett. 2008 Aug;30(8):1303-10
18418716
J Immunol Methods. 2004 May;288(1-2):149-64
15183093
J Immunol Methods. 2005 May;300(1-2):146-59
15946674
Cell Struct Funct. 2001 Feb;26(1):25-35
11345501